Equity Overview
Price & Market Data
Price: $3.65
Daily Change: +$0.13 / 3.56%
Daily Range: $3.52 - $3.71
Market Cap: $126,669,664
Daily Volume: 14,043
Performance Metrics
1 Week: -3.03%
1 Month: -12.00%
3 Months: 195.8%
6 Months: 80.51%
1 Year: 164.7%
YTD: 60.00%
Company Details
Employees: 66
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.